KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Tax Provisions (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 15 years of Tax Provisions data on record, last reported at $139.9 million in Q4 2025.

  • For Q4 2025, Tax Provisions fell 37.4% year-over-year to $139.9 million; the TTM value through Dec 2025 reached $690.0 million, down 12.0%, while the annual FY2025 figure was $690.0 million, 12.0% down from the prior year.
  • Tax Provisions reached $139.9 million in Q4 2025 per VRTX's latest filing, down from $215.9 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $257.9 million in Q4 2022 and bottomed at -$111.2 million in Q2 2021.
  • Average Tax Provisions over 5 years is $176.6 million, with a median of $192.2 million recorded in 2022.
  • Peak YoY movement for Tax Provisions: crashed 789.6% in 2021, then surged 292.36% in 2022.
  • A 5-year view of Tax Provisions shows it stood at $100.8 million in 2021, then surged by 155.85% to $257.9 million in 2022, then crashed by 30.67% to $178.8 million in 2023, then grew by 25.0% to $223.5 million in 2024, then plummeted by 37.4% to $139.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $139.9 million in Q4 2025, $215.9 million in Q3 2025, and $250.1 million in Q2 2025.